(Q42999489)

English

Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors

scientific article published in October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

3

object named as

Fred Saad

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

N Simon Tchekmedyian

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yin-Miao Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Cancer Investigation

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

849-855

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Cox's Regression Model for Counting Processes: A Large Sample Study

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483508

21 January 2018

Identifiers

10.3109/07357907.2010.483508

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42999489&oldid=1976325594"